Let’s dive into some prime choices out of the screener.<\/p>\n
Simply Wall St Growth Rating: \u2605\u2605\u2605\u2605\u2605\u2606<\/p>\n
Overview: Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS, oncology, and hematology disorders, with a market cap of \u20ac220.14 million.<\/p>\n
Operations: The company generates revenue primarily from its biotechnology segment, amounting to \u20ac10.93 million.<\/p>\n
Insider Ownership: 13.9%<\/p>\n
Oryzon Genomics demonstrates potential as a growth company with high insider ownership in Europe. Despite reporting a net loss of \u20ac2.61 million for 2025, sales increased to \u20ac10.93 million from the previous year, indicating revenue growth momentum. The European Medicines Agency’s approval of Oryzon\u2019s Phase II study for iadademstat highlights its strong clinical pipeline, particularly in oncology and hematology. Forecasts suggest significant revenue growth at 47.9% annually, outpacing the Spanish market significantly.<\/p>\n
Simply Wall St Growth Rating: \u2605\u2605\u2605\u2605\u2605\u2605<\/p>\n Overview: Egetis Therapeutics AB is a pharmaceutical company specializing in late-stage development projects for treating serious diseases with unmet medical needs in the orphan drug segment, with a market cap of SEK2.37 billion.<\/p>\n Operations: The company’s revenue is primarily derived from its products Emcitate, generating SEK62.30 million, and Aladote, contributing SEK0.10 million.<\/p>\n Insider Ownership: 11.3%<\/p>\n Egetis Therapeutics is positioned for substantial growth, driven by its high insider ownership and promising pipeline. The company’s lead drug, Emcitate (tiratricol), has received FDA Priority Review for MCT8 deficiency, a rare condition with no approved U.S. treatments. Expected revenue growth of 53.5% annually surpasses the Swedish market significantly. Despite a net loss of SEK 342.5 million in 2025, Egetis is forecasted to become profitable within three years, reflecting its potential in the biotech sector.<\/p>\n Simply Wall St Growth Rating: \u2605\u2605\u2605\u2605\u2606\u2606<\/p>\n Overview: Idun Industrier AB (publ) is an investment holding company that focuses on investing in and developing industrial and service businesses across Sweden, the Nordic countries, Europe, and internationally, with a market cap of SEK3.64 billion.<\/p>\n Operations: The company’s revenue is derived from two main segments: Manufacturing, which accounts for SEK1.43 billion, and Service & Maintenance, contributing SEK866 million.<\/p>\n Insider Ownership: 32.4%<\/p>\n Idun Industrier is poised for significant growth, with earnings expected to increase by 20.64% annually over the next three years, outpacing the Swedish market’s 9.8%. Despite a high debt level and low forecasted return on equity of 13.5%, its revenue growth of 10.3% per year surpasses the market average of 0.9%. Trading at a substantial discount to its estimated fair value, Idun offers potential upside as it prepares to release fiscal year results on March 26, 2026.<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and\/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.<\/p>\n Companies discussed in this article include BME:ORY OM:EGTX and OM:IDUN B.<\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"As European markets rally on the back of a U.S.-Iran ceasefire, investor sentiment has been buoyed by optimism…\n","protected":false},"author":2,"featured_media":4224,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1153,525,15,483,2095,592,591,640,2219,351],"class_list":{"0":"post-12918","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-europe","8":"tag-biopharmaceutical-company","9":"tag-earnings-growth","10":"tag-european","11":"tag-european-markets","12":"tag-european-medicines-agency","13":"tag-growth-companies","14":"tag-insider-ownership","15":"tag-market-cap","16":"tag-pharmaceutical-company","17":"tag-revenue-growth"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/12918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/comments?post=12918"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/12918\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media\/4224"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media?parent=12918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/categories?post=12918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/tags?post=12918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"BME:ORY](\"https:\/\/www.europesays.com\/europe\/wp-content\/uploads\/2026\/04\/603c34494b8e67ca77f1055f11f3bb17.png\")
<\/a> BME:ORY Ownership Breakdown as at Apr 2026 <\/p>\n<\/a> OM:EGTX Earnings and Revenue Growth as at Apr 2026 <\/p>\n
<\/a> OM:IDUN B Ownership Breakdown as at Apr 2026 <\/p>\n